Related Experiment Video
Updated: Sep 29, 2025
12:26
Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
Published on: May 3, 2018
18.8K
Targeting CDK4 and CDK6 in cancer.
Shom Goel1,2, Johann S Bergholz3,4,5, Jean J Zhao6,7,8
1Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. shom.goel@petermac.org.
Nature Reviews. Cancer
|March 19, 2022
Summary
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are vital cancer treatments that halt cell cycle progression. Emerging research reveals broader applications and challenges like resistance, necessitating further clinical investigation.
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- Cyclin-dependent kinase 4 (CDK4) and CDK6 are crucial for cell cycle progression into S phase.
- CDK4/6 inhibitors are established treatments for advanced hormone receptor-positive breast cancer, inducing G1 cell cycle arrest.
Purpose of the Study:
- To provide a framework for understanding CDK4/6 inhibitor activity in cancer.
- To explore new therapeutic opportunities, combination regimens, and expanded cancer applications.
- To discuss mechanisms of CDK4/6 inhibitor resistance and future clinical development.
Main Methods:
- Review of current literature on CDK4/6 inhibitors.
- Analysis of emerging mechanisms of action beyond cell cycle arrest.
- Discussion of clinical trial data and resistance pathways.
Main Results:
- CDK4/6 inhibitors have effects beyond G1 arrest, suggesting wider therapeutic potential.
- New insights identify opportunities for novel combination therapies and expanded cancer indications.
- Understanding resistance mechanisms is critical for optimizing treatment strategies.
Conclusions:
- CDK4/6 inhibitors offer significant therapeutic benefits but face challenges like resistance.
- Further clinical exploration is urgently needed to realize the full potential of these agents.
- A conceptual framework can guide future development and application of CDK4/6 inhibitors in oncology.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.4K
11:44Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
7.7K
Related Concept Videos
02:34Inhibition of Cdk Activity
5.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
02:15M-Cdk Drives Transition Into Mitosis
5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
02:57Targeted Cancer Therapies
7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.9K
02:39Positive Regulator Molecules
5.7K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.7K
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
8.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K